ArticleJournal of dental sciences2026
Role of three-phase bone scintigraphy and fluorodeoxyglucose positron emission tomography in monitoring hyperbaric oxygen therapy combined with conservative surgery for refractory osteomyelitis.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: The anti-inflammatory effect of hyperbaric oxygen therapy (HBOT) on osteomyelitis of the jaw has not been sufficiently quantified. In this study, we aimed to quantitatively evaluate the effects of HBOT and postoperative disease status in patients with jaw osteomyelitis treated with minimally invasive surgery combined with HBOT using nuclear medicine imaging. Materials and methods: The study included 11 patients who underwent sequestrectomy or saucerization and preoperative HBOT in our department between 2008 and 2015. The underlying etiologies were dental infection-related osteomyelitis (four cases; hereinafter ODONT group), osteoradionecrosis (four cases; hereinafter ORN group), or medication-related osteonecrosis of the jaw (three cases; hereinafter medication-related osteonecrosis of the jaw (MRONJ) group). Quantitative assessments were performed using SUVmax from fluorodeoxyglucose positron emission tomography (FDG-PET) and region-of-interest measurements from bone scintigraphy obtained before and after HBOT. Mean values and standard deviations were calculated, and pre-to post-treatment differences were defined as changes. Clinical cure was defined as the absence of symptom recurrence at 3 months postoperatively. Results: The overall cure rate at 3 months postoperatively was 90.9% (10/11 cases). The greatest magnitude of change was observed in the ODONT group for FDG-PET and in the ORN group for bone scintigraphy. Furthermore, post-treatment variability tended to be greater than pretreatment variability in the ORN group for FDG-PET and in the MRONJ group for bone scintigraphy. Conclusion: Nuclear medicine imaging may be helpful for quantitatively assessing the therapeutic effect of HBOT in jaw osteomyelitis and may contribute to improved treatment response evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.